Kasra Kasraian Biography and Net Worth

Revisit consent button Skip to Content PepGen Menu About Science EDO Platform Scientific Pub of PepGen

Kasra Kasraian servers as Chief Technical Officer at PepGen. He joined PepGen from bluebird bio, where he held various roles of increasing responsibility. Most recently, he served as Senior Vice President, Quality, Regulatory Affairs, and CMC Sciences. Prior to this role, he served as Senior Vice President, Technical Development and Operations, where he played a central role in the approval and launch of three gene therapy products—SKYSONA^™, ZYNTEGLO^™, and LYFGENIA^™. Prior to bluebird bio, Kasra led the Technical Operation, Quality, and Regulatory CMC functions at Zafgen, Inc. He also held scientific and leadership roles at Biogen, Wyeth Biotech, Pfizer Inc., and Genetics Institute in the areas of formulation development, process development, technical services, manufacturing, and CMC management encompassing early phase development through commercialization for both small molecules and biologics. During his tenure at Biogen, the CMC team he led guided the submission and approval of 3 BLAs/MAAs. Kasra earned his PhD in Pharmaceutical Sciences and his BS in Chemical Engineering from the University of Kentucky.

What is Kasra Kasraian's net worth?: The estimated net worth of Kasra Kasraian is at least $111.41 thousand as of May 21st, 2026. Dr. Kasraian owns 50,074 shares of PepGen stock worth more than $111,415 as of August 6th. This net worth estimate does not reflect any other investments that Dr. Kasraian may own. Learn More about Kasra Kasraian's net worth.
How do I contact Kasra Kasraian?: The corporate mailing address for Dr. Kasraian and other PepGen executives is , , . PepGen can also be reached via phone at 781-797-0979 and via email at [email protected]. Learn More on Kasra Kasraian's contact information.
Has Kasra Kasraian been buying or selling shares of PepGen?: Kasra Kasraian has not been actively trading shares of PepGen during the last ninety days. Most recently, Kasra Kasraian sold 1,233 shares of the business's stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $1.41, for a transaction totalling $1,738.53. Following the completion of the sale, the insider now directly owns 50,074 shares of the company's stock, valued at $70,604.34. Learn More on Kasra Kasraian's trading history.
Who are PepGen's active insiders?: PepGen's insider roster includes Kasra Kasraian (Revisit consent button Skip to Content PepGen Menu About Science EDO Platform Scientific Pub), and James McArthur (President and Chief Executive Officer). Learn More on PepGen's active insiders.
Are insiders buying or selling shares of PepGen?: During the last year, PepGen insiders bought shares 1 times. They purchased a total of 200,000 shares worth more than $640,000.00. During the last year, insiders at the sold shares 1 times. They sold a total of 1,233 shares worth more than $1,738.53. The most recent insider tranaction occured on May, 21st when insider Kasra Kasraian sold 1,233 shares worth more than $1,738.53. Insiders at PepGen own 1.3% of the company. Learn More about insider trades at PepGen.
Information on this page was last updated on 5/21/2026.

Kasra Kasraian Insider Trading History at PepGen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/21/2026	Sell	1,233	$1.41	$1,738.53	50,074

Kasra Kasraian Buying and Selling Activity at PepGen

PepGen Company Overview

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

Today's Range

Now: $2.35

$2.06

$2.39

50 Day Range

MA: $1.82

$1.35

$2.44

2 Week Range

Now: $2.35

$1.01

$7.80

Volume

3,157,325 shs

Average Volume

1,068,324 shs

Market Capitalization

$162.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.89